Cutaneous T-cell lymphoma

The PBS subsidises vorinostat for patients with cutaneous T-cell lymphoma (CTCL).

Treatment with vorinostat can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with CTCL.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing vorinostat.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe vorinostat for the treatment of CTCL in writing and:

All applications must include a completed:

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

We’re testing a new website design. Try it out and tell us what you think. Read more about changes to this site.

Page last updated: 3 July 2017

This information was printed Tuesday 25 July 2017 from humanservices.gov.au/health-professionals/enablers/cutaneous-t-cell-lymphoma It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.